CTAC
Pancreatic Ductal Adenocarcinoma (PDAC) Progress Working Group

Interim Report

James L. Abbruzzese
July 8, 2015
Working Group’s Purpose & Objectives

The primary purpose of the PDAC Progress WG is to monitor NCI’s progress of the Scientific Framework sent to Congress in February of 2014.

The Working Group’s main objectives are as follows:

• Assess NCI progress to date (short term)

• Provide recommendations for process of future annual assessment reports to CTAC (intermediate term)

• Review and update the scientific framework no later than 5 years after initial development (long term)

• Submit a report to Congress on the effectiveness of the scientific framework no later than 6 years after the initial development (long term)
Scientific Framework’s Four Initiatives & the Subgroups’ Assignments

• Initiative 1: Understanding the Biological Relationship between PDAC and Diabetes Mellitus (DM)
  – Rachael Stolzenberg-Solomon*, Jim Abbruzzese, Dana Andersen, Jane Holt, Murray Korc, Gloria Petersen, Sudhir Srivastava

• Initiative 2: Early Detection and Biomarkers
  – Gloria Petersen*, James Abbruzzese, Tony Hollingsworth, Jane Holt, Alison Klein, Murray Korc, David Mankoff, Lynn Matrisian, Sheila Prindiville, Sudhir Srivastava

• Initiative 3: New Therapeutic Strategies in Immunotherapies
  – Elizabeth Jaffee*, Jim Abbruzzese, Christine Alewine, Toby Hecht, Tony Hollingsworth, Jane Holt, Andrew Lowy

• Initiative 4: Development of RAS Therapeutics
  – Lynn Matrisian*, Debbie Jaffe, Murray Korc, Andrew Lowy, Sudhir Srivastava, David Tuveson

* Subgroups’ Facilitators
Scientific Framework’s Implementation Process: Initial Impressions

• All of the initiatives within the Scientific Framework are still relevant

• Initiative 1 (Relationship between PDAC and DM):
  Implementation progress is on target
  – NIDDK/NIBIB meeting, “Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease” July 22, 2015

• Initiative 2 (Early Detection and Biomarkers):
  Implementation progress is on target
Scientific Framework’s Implementation Process: Initial Impressions

• **Initiative 3 (Immunotherapy):**
  Implementation plan needs further assessment
  – Initiative would benefit from an additional meeting

• **Initiative 4 (Development of Ras Therapeutics):**
  Implementation plan has been launched; however, additional information is needed to assess progress
  - Learn more about FNLCR RAS project and relevance to PDAC
Next Steps

• Webinar with the entire Working Group to finalize recommendations from the initial review – July 16, 2015

• Distribute working group report to CTAC – November 4, 2015
Progress in PDAC WG Members

Chair: James Abbruzzese

Members:
Christine Alewine
Dana Andersen
Michael (Tony) Hollingsworth
Jane M. Holt
Elizabeth Jaffee
Alison Klein
Murray Korc
Andrew Lowy
David Mankoff
Lynn Matrisian
Gloria Petersen
Rachel Stolzenberg-Solomon
David Tuveson

NIH Liaisons:
Jeffrey Abrams
Dana Andersen
Amy Bulman
James Doroshow
Sarah Fabian
Samantha Finstad
Toby Hecht
Deborah Jaffe
LeeAnn Jensen
Bhupinder Mann
Sheila Prindiville
Sudhir Srivastava